x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAB-0012220
| Product Information | |
|---|---|
| Clonality | Polyclonal |
| Host Species | Rabbit |
| Reactivity | Human |
| Applications | WB, IP |
| Product Description | Polyclonal antibodies are produced by immunizing animals with a synthetic peptide corresponding to residues at the amino terminus of human LAT1 protein. Antibodies were purified by protein A and peptide affinity chromatography. |
| Format | Liquid |
| Purity | Affinity purity |
| Target Information | |
|---|---|
| Target Name | SLC7A5 |
| UniProt No. | Q01650 |
| Gene ID | 8140 |
| Gene Description | L-type amino acid transporter 1, also known as solute carrier family 7 member 5, is a high-affinity neutral transporter of larger amino acids. It facilitates the cellular amino acid uptake in a sodium independent manner and selectively transports D-and L-isomers of small neutral amino acids. LAT1 also regulates amino acid exchange in conjunction with solute carrier family 1 member 5. Transport of thyroid hormones across the placenta is established via LAT1 during normal fetal development. LAT1 promotes neuronal cell proliferation by regulating the transport of amino acids across the blood brain barrier. LAT1 is upregulated in various cancer types, including breast cancer, lung cancer, prostate cancer, and gliomas. High expression of LAT1 is detected in non-small cell lung cancer with lymph node metastases. Increased LAT1 expression is a novel biomarker of high grade malignancy in prostate cancers. Inhibition of LAT1 suppresses tumor cell growth in several tumor types. |
| Shipping & Storage | |
|---|---|
| Shipping | Shipped at 4 °C. |
| Storage Instructions | Store at –20 °C. Do not aliquot the antibody. |
| Storage Buffer | Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA and 50% glycerol. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
